NASDAQ:XENT Intersect ENT (XENT) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free XENT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$28.24▼$28.2450-Day Range$28.24▼$28.2452-Week Range$15.92▼$28.25Volume14,512 shsAverage Volume351,526 shsMarket Capitalization$954.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Intersect ENT alerts: Email Address Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Intersect ENT Stock (NASDAQ:XENT)Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.Read More Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. XENT Stock News HeadlinesOctober 21, 2023 | investing.comXENT Historical DataSeptember 12, 2023 | yahoo.comMusic At The Intersection Festival Tells St. Louis’ Rich Musical HistoryApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. August 28, 2023 | sfgate.comCruise car reportedly swerves in backhoe's way, is busted in SF intersectionJune 24, 2023 | cbsnews.comWoman ejected from car after being hit by driver doing donuts in Long Beach intersectionFebruary 22, 2023 | news.yahoo.comDrivers shut down Alexander County intersection during unsanctioned street takeoverFebruary 18, 2023 | washingtonpost.com4 levels of living space and a garage in D.C. Shaw’s neighborhoodJuly 15, 2022 | benzinga.comNalu Medical, Inc. Names Thomas West President...April 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. July 14, 2022 | finance.yahoo.comNalu Medical, Inc. Names Thomas West President and Chief Executive OfficerMay 12, 2022 | finance.yahoo.comMedtronic will sell Intersect ENT subsidiary Fiagon to Hemostasis to win FTC approval of acquisitionApril 28, 2022 | finance.yahoo.comDexCom (DXCM) Misses Q1 Earnings EstimatesApril 20, 2022 | finance.yahoo.comThose who invested in Intersect ENT (NASDAQ:XENT) five years ago are up 55%February 24, 2022 | finance.yahoo.comTeleflex (TFX) Q4 Earnings and Revenues Surpass EstimatesFebruary 17, 2022 | seekingalpha.comMedtronic, Intersect ENT said to finalize divestiture plans to help with antitrust concernsJanuary 25, 2022 | nasdaq.comIntersect ENT: Real-world Data Support Use Of PROPEL In Patients Undergoing Endoscopic Sinus SurgeryJanuary 25, 2022 | stockhouse.comReal-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource UtilizationJanuary 25, 2022 | finance.yahoo.comReal-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource UtilizationDecember 2, 2021 | finance.yahoo.comWhy Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?November 30, 2021 | nasdaq.comIs Intersect ENT (NASDAQ:XENT) Using Too Much Debt?November 18, 2021 | finance.yahoo.comIntersect ENT's (XENT) Sell-Off on Track Amid COVID WoesNovember 3, 2021 | finance.yahoo.comIntersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On TrackNovember 2, 2021 | finance.yahoo.comIntersect ENT Reports Third Quarter 2021 Financial ResultsOctober 28, 2021 | finance.yahoo.comFirst Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in EuropeOctober 22, 2021 | finance.yahoo.comHow Many Intersect ENT, Inc. (NASDAQ:XENT) Shares Do Institutions Own?September 22, 2021 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XENT, INOV, HOMB, IDEX; Shareholders are Encouraged to Contact the FirmSeptember 14, 2021 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SBKK, SAFM, LMRK, XENT; Shareholders are Encouraged to Contact the FirmSee More Headlines Receive XENT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:XENT CUSIPN/A CIK1271214 Webwww.intersectent.com Phone(650) 641-2100Fax866-736-1251Employees433Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-159,630,000.00 Net Margins-161.94% Pretax Margin-163.16% Return on Equity-709.52% Return on Assets-48.18% Debt Debt-to-Equity Ratio6.89 Current Ratio1.88 Quick Ratio1.50 Sales & Book Value Annual Sales$106.75 million Price / Sales8.95 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-13.71Miscellaneous Outstanding Shares33,814,000Free Float33,104,000Market Cap$954.91 million OptionableOptionable Beta1.45 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Thomas A. West (Age 58)Pres, CEO & Director Comp: $908.97kMr. Richard A. Meier (Age 62)Exec. VP & CFO Comp: $621.76kMr. Patrick A. Broderick (Age 63)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $138.46kMs. Reyna M. FernandezChief Human Resource OfficerMr. Drake R. Parker (Age 58)Advisor of Strategic Initiatives Key CompetitorsAntares PharmaNASDAQ:ATRSMiMedx GroupNASDAQ:MDXGArtivionNYSE:AORTParagon 28NYSE:FNAAtriCureNASDAQ:ATRCView All Competitors XENT Stock Analysis - Frequently Asked Questions How were Intersect ENT's earnings last quarter? Intersect ENT, Inc. (NASDAQ:XENT) issued its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The medical equipment provider had revenue of $24.40 million for the quarter, compared to the consensus estimate of $29.63 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%. What is Thomas West's approval rating as Intersect ENT's CEO? 7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Intersect ENT own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV). This page (NASDAQ:XENT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intersect ENT, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
